The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review (Q37326585)

19 August 2017

0 references

1 reference

title

The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review (English)

1 reference

polycystic ovary syndrome

19 August 2017

1 reference

1 reference

1 reference

1 reference

Zhang Jing

1

1 reference

19 August 2017

Xu Liang-Zhi

2

1 reference

19 August 2017

Wu Tai-Xiang

3

1 reference

19 August 2017

Tang Ying

4

1 reference

19 August 2017

Jia Yu-Jian

5

1 reference

19 August 2017

1 October 2008

1 reference

Gynecological Endocrinology

19 August 2017

1 reference

19 August 2017

24

1 reference

19 August 2017

10

1 reference

19 August 2017

590-600

1 reference

The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.

19 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Insulin-lowering medications in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590802288242

10.1080/09513590802288242

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference